Poly Medicure Future Growth
Future criteria checks 5/6
Poly Medicure is forecast to grow earnings and revenue by 24.6% and 20.5% per annum respectively. EPS is expected to grow by 23.8% per annum. Return on equity is forecast to be 16.2% in 3 years.
Key information
24.6%
Earnings growth rate
23.8%
EPS growth rate
| Medical Equipment earnings growth | 22.2% |
| Revenue growth rate | 20.5% |
| Future return on equity | 16.2% |
| Analyst coverage | Good |
| Last updated | 10 Jan 2025 |
Recent future growth updates
Recent updates
Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business
Jan 28
Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?
Dec 28With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case
Dec 10Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge
Nov 02Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 20Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00
Sep 14After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar
Sep 06Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet
Aug 14Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138
Jul 27Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)
Jul 11Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations
May 25Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital
May 12Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up
Mar 23Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today
Feb 15Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 16Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?
Nov 14Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward
Oct 24Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 22Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Aug 12Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching
Jul 13Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return
Jun 16Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital
Mar 02We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Feb 14Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal
Oct 16We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Sep 28Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Jun 25A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)
Jun 07Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends
May 23With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Feb 23There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital
Feb 04Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 12With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Oct 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 25,290 | 5,443 | 2,971 | 5,005 | 5 |
| 3/31/2026 | 20,843 | 4,351 | 1,955 | 4,010 | 6 |
| 3/31/2025 | 17,028 | 3,387 | 1,011 | 3,436 | 6 |
| 9/30/2024 | 15,225 | 2,949 | -544 | 2,526 | N/A |
| 6/30/2024 | 14,397 | 2,696 | N/A | N/A | N/A |
| 3/31/2024 | 13,758 | 2,583 | -109 | 2,661 | N/A |
| 12/31/2023 | 13,046 | 2,487 | N/A | N/A | N/A |
| 9/30/2023 | 12,498 | 2,337 | -197 | 2,390 | N/A |
| 6/30/2023 | 11,872 | 2,150 | N/A | N/A | N/A |
| 3/31/2023 | 11,152 | 1,793 | -482 | 1,911 | N/A |
| 12/31/2022 | 10,659 | 1,566 | N/A | N/A | N/A |
| 9/30/2022 | 10,113 | 1,411 | -533 | 1,568 | N/A |
| 6/30/2022 | 9,600 | 1,359 | N/A | N/A | N/A |
| 3/31/2022 | 9,231 | 1,465 | -321 | 1,235 | N/A |
| 12/31/2021 | 8,785 | 1,492 | N/A | N/A | N/A |
| 9/30/2021 | 8,518 | 1,500 | -228 | 777 | N/A |
| 6/30/2021 | 8,280 | 1,468 | N/A | N/A | N/A |
| 3/31/2021 | 7,865 | 1,359 | 236 | 1,187 | N/A |
| 12/31/2020 | 7,448 | 1,197 | N/A | N/A | N/A |
| 9/30/2020 | 7,218 | 1,094 | 347 | 1,543 | N/A |
| 6/30/2020 | 6,960 | 1,028 | N/A | N/A | N/A |
| 3/31/2020 | 6,872 | 959 | 223 | 1,283 | N/A |
| 12/31/2019 | 6,881 | 947 | N/A | N/A | N/A |
| 9/30/2019 | 6,625 | 858 | 603 | 1,197 | N/A |
| 6/30/2019 | 6,388 | 719 | N/A | N/A | N/A |
| 3/31/2019 | 6,108 | 654 | 285 | 1,065 | N/A |
| 3/31/2018 | 5,204 | 706 | N/A | 750 | N/A |
| 3/31/2017 | 4,550 | 551 | N/A | 561 | N/A |
| 3/31/2016 | 4,123 | 483 | N/A | 632 | N/A |
| 3/31/2015 | 3,903 | 623 | N/A | 633 | N/A |
| 3/31/2014 | 3,222 | 451 | N/A | 661 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: POLYMED's forecast earnings growth (24.6% per year) is above the savings rate (6.7%).
Earnings vs Market: POLYMED's earnings (24.6% per year) are forecast to grow faster than the Indian market (17.9% per year).
High Growth Earnings: POLYMED's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: POLYMED's revenue (20.5% per year) is forecast to grow faster than the Indian market (10.9% per year).
High Growth Revenue: POLYMED's revenue (20.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: POLYMED's Return on Equity is forecast to be low in 3 years time (16.2%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 19:52 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Poly Medicure Limited is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Karan Khanna | Ambit Capital |
| Sunita Vaidyanathan | Brics Securities Limited |